Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space

 
• By Jessica Merrill
  
Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.
Novartis' Kisqali is the first CDK4/6 inhibitor to show a survival advantage
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences